VR Logo

Equillium Inc. (EQ) download report


Healthcare | Biotechnology & Pharma Research

Equillium Inc. (EQ) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need.

IPO Date: 11-Oct-2018

Exec. Chairman: Mr. Daniel Mark Bradbury

Co-Founder, CEO & Director: Mr. Bruce D. Steel C.F.A.

Listing: NASDAQ: EQ

Country: United States

Headquarters: La Jolla, CA

Website: https://equilliumbio.com

Key Facts

Market cap: $72.32 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-67.48 Mln

Cash: $68.82 Mln

Total Debt: $11.77 Mln

Insider's Holding: 31.97%

Liquidity: Low

52 Week range: $1.66 - 7.12

Shares outstanding: 34,275,900

5 Years Aggregate:

  • CFO: $-87.97 Mln
  • EBITDA: $-103.77 Mln
  • Net Profit: $-109.98 Mln

Stock Performance

Time Period Equillium (EQ) S&P BSE Sensex S&P Small-Cap 600
YTD-44.03-9.18-18.78
1 month-15.26-4.78-8.00
3 months-33.02-9.66-13.65
1 Year-64.180.81-17.19
3 Years-28.0310.336.10
5 Years--11.345.87
10 Years--11.749.84
As on 01-Jul-2022
Year Equillium (EQ) S&P Small-Cap 600 S&P BSE Sensex
2021-29.5325.2721.99
202058.289.5715.75
2019-58.5820.8614.38